The Warfarin/Aspirin Study in Heart failure

What is the most cost effective anti-thrombotic strategy to reduce mortality in heart failure? The WASH Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN76146656

Enrollment

279

Registered

2004-01-23

Start date

1995-11-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart disease Circulatory System Heart disease

Interventions

1. Aspirin 2. Wafarin 3. No anti-thrombotic treatment

Eligibility

Inclusion criteria

Inclusion criteria: Patients were being treated for heart failure, and had evidence of ventricular dysfunction to a defined level on echocardiography.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Secondary

Measure	Time frame
Not provided at time of registration	—

Primary

Measure	Time frame
1. Deaths 2. Myocardial infarction 3. Stroke 4. Bleeding episodes 5. Dyspepsia 6. A number of laboratory tests	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026